Research Article

You have full text access to this OnlineOpen article

Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985

  1. Theodore Pincus1,4,*,
  2. Tuulikki Sokka1,2,
  3. Hannu Kautiainen3

Article first published online: 7 APR 2005

DOI: 10.1002/art.20941

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 52, Issue 4, pages 1009–1019, April 2005

Additional Information

How to Cite

Pincus, T., Sokka, T. and Kautiainen, H. (2005), Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis & Rheumatism, 52: 1009–1019. doi: 10.1002/art.20941

Author Information

  1. 1

    Vanderbilt University, Nashville, Tennessee

  2. 2

    Jyväskylä Central Hospital, Jyvaskyla, Finland

  3. 3

    Rheumatism Foundation Hospital, Heinola, Finland

  4. 4

    Vanderbilt University, Nashville, Tennessee

*Division of Rheumatology and Immunology, Vanderbilt University School of Medicine, 203 Oxford House, Box 5, Nashville, TN 37232-4500

Publication History

  1. Issue published online: 7 APR 2005
  2. Article first published online: 7 APR 2005
  3. Manuscript Accepted: 13 DEC 2004
  4. Manuscript Received: 23 MAR 2004

Funded by

  • Abbott Immunology
  • Amgen
  • Arthritis Foundation
  • Aventis
  • Centocor
  • Pfizer
  • Jack C. Massey Foundation
  • Academy of Finland
  • NIH. Grant Number: HL-67964

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (135K)

REFERENCES

  • 1
    Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989; 16: 565–7.
  • 2
    Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989; 18 Suppl 79: 67–96.
  • 3
    Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy. J Rheumatol 1990; 17 Suppl 22: 12–5.
  • 4
    Pincus T. The case for early intervention in rheumatoid arthritis. J Autoimmun 1992; 5 Suppl A: 209–26.
  • 5
    Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol 1994; 23 Suppl 100: 21–30.
  • 6
    Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944–7.
  • 7
    Weinblatt ME. Rheumatoid arthritis: treat now, not later! [editorial]. Ann Intern Med 1996; 124: 773–4.
  • 8
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22.
  • 9
    Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131: 768–74.
  • 10
    Bergstrom U, Book C, Lindroth Y, Marsal L, Saxne T, Jacobsson L. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol 1999; 28: 160–5.
  • 11
    Porter DR, Capell HA, McInnes I, Munro R, Madhok R, Hunter JA, et al. Is rheumatoid arthritis becoming a milder disease? Or are we starting second-line therapy in patients with milder disease? Br J Rheumatol 1996; 35: 1305–8.
  • 12
    Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003; 115: 371–6.
  • 13
    Heikkila S, Isomaki H. Long-term outcome of rheumatoid arthritis has improved. Scand J Rheumatol 1994; 23: 13–5.
  • 14
    Sokka TM, Kaarela K, Mottonen TT, Hannonen PJ. Conventional monotherapy compared with a “sawtooth” treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999; 17: 527–32.
  • 15
    Sokka T, Kautiainen H, Hakkinen K, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis: results of 3 cohorts over 5 years. J Rheumatol 2004; 31: 1073–82.
  • 16
    Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14–21.
    Direct Link:
  • 17
    Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7.
  • 18
    Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti–tumor necrosis factor α agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313–8.
    Direct Link:
  • 19
    Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138–46.
  • 20
    Moreland LW, Baumgartner SW, Schiff MH, Tindall E, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7.
  • 21
    Lipsky PE, van der Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  • 22
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204.
    Direct Link:
  • 23
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45.
    Direct Link:
  • 24
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729–40.
    Direct Link:
  • 25
    Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579–81.
  • 26
    Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol 1993; 20: 575–8.
  • 27
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864–72.
    Direct Link:
  • 28
    Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res 1992; 5: 130–6.
    Direct Link:
  • 29
    Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34: 660–8.
    Direct Link:
  • 30
    Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208–13.
  • 31
    Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996; 35: 1106–15.
  • 32
    Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996; 35: 1263–8.
  • 33
    Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381–94.
    Direct Link:
  • 34
    Graudal N, Tarp U, Jurik AG, Galloe AM, Garred P, Milman N, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. J Rheumatol 2000; 27: 47–57.
  • 35
    Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001; 28: 2400–8.
  • 36
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–17.
    Direct Link:
  • 37
    Pincus T, Sokka T. Partial control of core data set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term damage: evidence from longitudinal observations over 5-20 years. Clin Exp Rheumatol 2002; 20 Suppl 27: S42–8.
  • 38
    Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. J Rheumatol 2000; 27: 2727–30.
  • 39
    Fries JF. A data bank for the clinician? [editorial]. N Engl J Med 1976; 294: 1400–2.
  • 40
    Moses LE. The series of consecutive cases as a device for assessing outcomes of intervention. N Engl J Med 1984; 311: 705–10.
  • 41
    Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight–joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989; 32: 531–7.
    Direct Link:
  • 42
    Fuchs HA, Callahan LF, Kaye JJ, Brooks RH, Nance EP, Pincus T. Radiographic and joint count findings of the hand in rheumatoid arthritis: related and unrelated findings. Arthritis Rheum 1988; 31: 44–51.
    Direct Link:
  • 43
    Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585–91.
  • 44
    Olsen NJ, Callahan LF, Brooks RH, Nance EP, Kaye JJ, Stastny P, et al. Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988; 84: 257–64.
  • 45
    Pincus T, Callahan LF. Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992; 19: 1051–7.
  • 46
    Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989; 110: 259–66.
  • 47
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 48
    Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240–51.
  • 49
    Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26–34.
  • 50
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 51
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346–53.
    Direct Link:
  • 52
    Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220–30.
    Direct Link:
  • 53
    Pincus T, Brooks RH, Callahan LF. Reliability of grip strength, walking time and button test performed according to a standard protocol. J Rheumatol 1991; 18: 997–1000.
  • 54
    Wolfe F, Pincus T. Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum 1999; 42: 1797–808.
    Direct Link:
  • 55
    Pincus T, Brooks RH, Callahan LF. A proposed standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. JRheumatol 1999; 26: 473–80.
  • 56
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 57
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 481–91.
  • 58
    Pincus T, Sokka T. Reply to: Swollen joint count as a predictor of response to anti–tumor necrosis factor α therapy in rheumatoid arthritis: comment on the article by Sokka and Pincus [letter]. Arthritis Rheum 2003; 48: 3613–5.
    Direct Link:
  • 59
    Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50: 2072–81.
    Direct Link:
  • 60
    Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, and the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568–73.
  • 61
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50.
    Direct Link:
  • 62
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–9.
  • 63
    Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet 1999; 353: 400–3.
  • 64
    Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of β, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 “negative” trials. N Engl J Med 1978; 299: 690–4.
  • 65
    Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301: 1410–2.
  • 66
    Freireich EJ. The randomized clinical trial as an obstacle to clinical research. In: VarcoRL, DelaneyJP, editors. Controversy in surgery. Philadelphia: WB Saunders; 1983. p. 5–12.
  • 67
    Feinstein AR. An additional basic science for clinical medicine. II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544–50.
  • 68
    Diamond GA, Forrester JS. Clinical trials and statistical verdicts: probable grounds for appeal. Ann Intern Med 1983; 98: 385–94.
  • 69
    Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983; 309: 1358–61.
  • 70
    Bombardier C, Tugwell P. Controversies in the analysis of longterm clinical trials of slow acting drugs [editorial]. J Rheumatol 1985; 12: 403–5.
  • 71
    Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037–41.
  • 72
    Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 1989; 10: 31–56.
  • 73
    Felson DT, Anderson JJ, Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials [review]. Arthritis Rheum 1990; 33: 140–9.
    Direct Link:
  • 74
    Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008–14.
  • 75
    Pincus T. Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; 23 Suppl 1: 2–10.
  • 76
    Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 15 Suppl 17: S27–38.
  • 77
    Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidence-based medicine.” Am J Med 1997; 103: 529–35.
  • 78
    Horwitz RI. Clinical versus statistical considerations in the design and analysis of clinical research. J Clin Epidemiol 1998; 51: 305–7.
  • 79
    Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887–92.
  • 80
    Kvien TK, Mikkelsen K, Nordvag B. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003; 30: 1135–7.
  • 81
    Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551–6.
  • 82
    Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8–17.
  • 83
    Isomaki HA, Mutru O, Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975; 4: 205–8.
  • 84
    Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75 Suppl 6A: 69–73.
  • 85
    Pincus T, Keysor J, Sokka T, Krishnan E, Callahan LF. Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. J Rheumatol 2004; 31: 229–34.
  • 86
    Pincus T, Callahan LF. The ‘side effects’ of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993; 32 Suppl 1: 28–37.
  • 87
    Silman A, Davies P, Currey HL, Evans SJ. Is rheumatoid arthritis becoming less severe? J Chronic Dis 1983; 36: 891–7.
  • 88
    Aho K, Tuomi T, Palosuo T, Kaarela K, von Essen R, Isomaki H. Is seropositive rheumatoid arthritis becoming less severe? Clin Exp Rheumatol 1989; 7: 287–90.
  • 89
    Spector TD, Hart DJ, Powell RJ. Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis 1993; 52: 254–7.
  • 90
    Silman AJ. The changing face of rheumatoid arthritis: why the decline in incidence? [editorial]. Arthritis Rheum 2002; 46: 579–81.
    Direct Link:
View Full Article (HTML) Get PDF (135K)